In 2012 the European Cardiovascular Research Institute (ECRI) was founded as a European collaborative effort to perform Investigator Sponsored Studies in the field of cardiology.
Dessolve III - Study Purpose
Study objective
To compare the MiStent with the XIENCE with respect to target lesion failure (TLF) at 12 months in a non-inferiority trial in a “real world” patient population.
Primary endpoint
The primary endpoint for this trial is a non-inferiority comparison of a device-oriented composite endpoint (DOCE) or TLF of the MiStent group to the XIENCE group at 12 months post-procedure. TLF is a composite of clinical endpoint of cardiac death, myocardial infarction not clearly attributable to a nontarget vessel and clinically-indicated target lesion revascularization (TLR).